Clinical trial · Interventional
TCM in the Treatment of Lung Adenocarcinoma
Efficacy and Safety of Jing-yuan-kang Granule in the Treatment of Lung Adenocarcinoma
NCT04482829CI-TRIAL-00046128unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Adenocarcinoma | Lung Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Jing-yan-kang Granule | Drug | — | UNRESOLVED |
| PC chemotherapy and symptomatic treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental Group
- description
- On the basis of PC chemotherapy and symptomatic treatment, the patients in the experimental group will receive jing-yuan-kang granule with one dose daily.
- interventionNames
- Drug: Jing-yan-kang Granule
- Drug: PC chemotherapy and symptomatic treatment
- type
- OTHER
- label
- Control Group
- description
- All the patients in control group will receive PC chemotherapy and symptomatic treatment without other treatment.
- interventionNames
- Drug: PC chemotherapy and symptomatic treatment
Primary outcomes (2)
- measure
- The quality of life will be evaluated by The European Organization for Research and Treatment of Cancer Quality of life Questinnaire Core-30(EORTC QLQ-C30) scale
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * A confirmed diagnosis of LADC. * Age ranges from17years to75years. * A KPS score ≥40. * Without radiotherapy, immunotherapy and targeted therapy. * Without participanting in any other trial. * With signed informed consent. Exclusion Criteria: * Pregnant, nursing or may become pregnant women. * The patient has a history of allergy to any of the components of the intervention drug; * Patients with severe liver and kidney dysfunction, cardiovascular and cerebrovascular diseases. * Unconscious or unable to communicate normally. * Patients with poor compliance.
References
Publications (0)
Data not yet available
No reference posted for this study.